title: Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.
abstract: Impulse control disorders (ICDs) are a known side effect of dopamine replacement therapy in patients with Parkinson's disease (PD). They can have devastating consequences for patients and their families.
authors.forename: L
authors.initials: L
authors.lastname: Wilson
authors.forename: J
authors.initials: J
authors.lastname: Sheehan
authors.forename: M
authors.initials: M
authors.lastname: Thorpe
mesh_terms: D000328:Adult; D000547:Amantadine / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D052160:Benzothiazoles / Q000009:adverse effects; D002230:Carbidopa / Q000009:adverse effects; D002396:Catechols / Q000009:adverse effects; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000139:chemically induced*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007189:Indans / Q000009:adverse effects; D007211:Indoles / Q000009:adverse effects; D007980:Levodopa / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy*; D000077487:Pramipexole; D012642:Selegiline / Q000009:adverse effects
chemical_list: D000978:Antiparkinson Agents; D052160:Benzothiazoles; D002396:Catechols; D004338:Drug Combinations; D007189:Indans; D007211:Indoles; D018696:Neuroprotective Agents; C481098:Stalevo; C031967:rasagiline; C046649:ropinirole; D012642:Selegiline; D007980:Levodopa; D000077487:Pramipexole; D000547:Amantadine; D002230:Carbidopa